Manipal Cure and Care Launches Hand Sanitizer
Manipal Cure and Care has launched its Hand Sanitizer (Hand SanTyzer), a Rub-In Hand and Skin Disinfectant Fluid. The formulation is a combination of Iso-propyl Alcohol, 1-propanol and

Manipal Cure and Care has launched its Hand Sanitizer (Hand SanTyzer), a Rub-In Hand and Skin Disinfectant Fluid. The formulation is a combination of Iso-propyl Alcohol, 1-propanol and

Sinovac Biotech (Sinovac) has received a Certificate of Approval from the Secretaria de Salud to distribute PANFLU.1, its H1N1 pandemic influenza (swine flu) vaccine, in Mexico. The certificate

Aethlon will contribute into ESI all exosome-related patents and patents pending. Jim Joyce, chairman and chief executive officer of Aethlon said, “The ability to reduce circulating exosomes would

Bayer China has installed Sepha’s BlisterScan as a part of its quality assurance processes. BlisterScan is a non-destructive method of quality control which tests for leaks in blisterpacks

Merck has reported financial results for the third quarter of 2009. Net income for the third quarter was $3,424.3m, compared with $1,092.7m in 2008 during the same period.

Their project is one of 76 grants announced by the Gates Foundation in the third funding round of Grand Challenges Explorations. To receive funding Wright and Haselton showed

The Gen-Probe’s complaint also alleges that BD’s ProbeTec Female Endocervical and Male Urethral Specimen Collection Kits for Amplified Chlamydia trachomatis/Neisseria gonorrhoeae (CT/GC) DNA Assays used with the Viper

Optigenex has entered into a supply and license Agreement with Suracell to provide its patented ingredient AC-11 for use in a focused nutritional and age management dietary supplement

BioStorage Technologies is expanding its European operations with the opening of a new 16,140 square foot (1,499 sq meters) full-service biorepository in Frankfurt, Germany. BioStorage’s expanded European operations

ISTA Pharmaceuticals has announced poster presentations of results from its Bepreve (bepotastine besilate ophthalmic solution) 1.5% phase 3 clinical studies in allergic conjunctivitis. The studies demonstrated that Bepreve